Gravity-Powered Biomedical Device Paves Way for Low Cost POC Diagnostic Testing
|
By LabMedica International staff writers Posted on 14 Jul 2023 |

The need for simple, user-friendly, point-of-care devices continues to exist. Many prototype and market-ready devices aim to simplify diagnosis and crucial biomarker measurement processes using minimal liquid samples, power, and professional knowledge. These innovations aim to enhance healthcare delivery for the vast population residing in low-resource locales, far from well-equipped hospitals and qualified medical personnel. These tests generally share certain prerequisites: they need to transport, combine, and assess minute biological sample-containing droplets and their active ingredients, enabling specific biomarker measurements. High-end devices employ miniature electric pumps to facilitate these reactions, while others leverage the dynamics of liquids within microchannels, or microfluidics, to produce a suction-like effect. Each method comes with its own distinct benefits and challenges. Now, researchers have demonstrated a first-of-its-kind approach that only uses gravity to power point-of-care biomedical devices and also offers certain advantages over currently existing platforms.
Biomedical engineers at Duke University (Durham, NC, USA) have devised a completely new approach for building point-of-care diagnostic tools, which only leverages gravity to transport, mix, and manipulate the liquid droplets involved. This proof-of-concept uses readily available materials and minimal power to interpret results, making it a potentially beneficial option for use in settings with limited resources. The innovative gravity-based technique is based on a selection of nine commercially available surface coatings that can fine-tune the wettability and slipperiness at any given point in the device, thereby controlling how much droplets spread into pancakes or remain spherical, while also influencing their ease of movement down an incline.
By using these surface coatings in smart combinations, all necessary microfluidic elements required for a point-of-care test can be generated. For instance, if a certain location is extremely slippery and a droplet is positioned at a juncture where one side pulls liquid flat and the other pushes it into a ball, it acts like a pump and accelerates the droplet toward the former. The scientists devised numerous elements to manage the motion, interaction, timing, and sequence of multiple droplets within the device. Merging these elements, they fabricated a prototype test to measure human serum lactate dehydrogenase (LDH) levels. They carved channels into the testing platform to create designated routes for droplet passage, each coated with a substance preventing droplets from sticking along the way. Specific points were also pre-treated with dried reagents needed for the test, which are absorbed by droplets of simple buffer solution as they traverse the channels.
The maze-like test is then sealed with a lid equipped with holes for the sample and buffer solution to be dripped in. Once filled, the test is inserted into a box-shaped device with a handle that rotates the test by 90 degrees, allowing gravity to take over. The device also features a simple LED and light detector for swift and easy color-based test result assessment. This enables the scientists to label three different biomarkers with distinct colors for varying tests. In the LDH prototype test, the biomarker is marked with a blue molecule. A basic microcontroller measures the depth of the blue tint and the rate of color change, signifying the quantity and concentration of LDH in the sample, to yield results. This novel demonstration presents a new approach to the development of affordable, low-energy, point-of-care diagnostic devices. While the team intends to further refine their concept, they also hope it will spark interest and lead to the creation of similar tests by other researchers.
“Most microfluidic devices need more than just capillary forces to operate,” said Ashutosh Chilkoti, the Alan L. Kaganov Distinguished Professor of Biomedical Engineering at Duke. “This approach is much simpler and also allows very complex fluid paths to be designed and operated, which is not easy or cheap to do with microfluidics.”
Related Links:
Duke University
Latest Technology News
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
Channels
Clinical Chemistry
view channel
Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth
Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more
Blood-Based Alzheimer’s Testing Platform Offers Rapid Results
Accurate identification of Alzheimer’s disease pathology often relies on cerebrospinal fluid analysis or positron emission tomography, which can be invasive, costly, and not widely accessible.... Read more
Simple Oral Swab Monitors Persistent Inflammation in Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare lung disease that affects about one in 7,500 to 10,000 live births worldwide. Symptoms can begin in the newborn period and progress to recurrent respiratory infections... Read more
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read moreMolecular Diagnostics
view channel
Spatial Map Guides Treatment Selection in Muscle-Invasive Bladder Cancer
Muscle-invasive bladder cancer is clinically heterogeneous, with patients often responding very differently to therapy. Existing biomarkers do not fully explain these disparities, limiting precision treatment... Read more
Genomic Study Identifies Risk Regions for Intrahepatic Cholestasis of Pregnancy
Intrahepatic cholestasis of pregnancy (ICP) affects 0.2–2% of pregnancies and typically arises after 30 weeks, presenting with intense itching of the palms and soles. Diagnosis is confirmed by elevated... Read more
Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes
Respiratory syncytial virus, influenza, and SARS-CoV-2 remain major respiratory pathogens in ambulatory care. RSV is a particular priority because it can cause significant disease in infants, older adults,... Read more
Whole-Genome Sequencing Enables Genetic Diagnosis in Neurodevelopmental Disorders
Neurodevelopmental disorders include autism spectrum disorder and intellectual disability and can be difficult to diagnose because clinical presentations vary widely. In Italy, approximately 1% of children... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Lab-on-a-Chip Approach Advances Immune–Cancer Cell Interaction Analysis
Conventional cytotoxicity assays often average responses across thousands of cells, obscuring how individual immune cells engage and kill tumor cells. For immunotherapy evaluation, the precise sequence... Read more
Antibody Profiles Provide Clues to Long COVID Severity and Symptoms
Persistent symptoms after acute COVID-19 affect millions of people, causing fatigue, respiratory issues, and cognitive deficits that can be difficult to quantify with standard tests. Clinical teams lack... Read moreMicrobiology
view channel
Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread
Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more
Extracellular Vesicle Biomarker May Enable Noninvasive Monitoring of H. pylori
Helicobacter pylori infects an estimated 43.9% of the global population, affecting approximately 4.4 billion people worldwide. In many regions, including Africa, Eastern Europe, and Southeast Asia, prevalence... Read more
Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE
Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read morePathology
view channel
Stain-Free Imaging Platform Matches Standard Cancer Pathology
Histopathology underpins cancer diagnosis, but turnaround times and inter-laboratory variability can limit timely, consistent interpretation. Conventional staining relies on chemical dyes and multiple... Read more
New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools
QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more








